WO2007003904A3 - Compositions prophylactiques et immunomodulatrices et leurs utilisations - Google Patents

Compositions prophylactiques et immunomodulatrices et leurs utilisations Download PDF

Info

Publication number
WO2007003904A3
WO2007003904A3 PCT/GB2006/002424 GB2006002424W WO2007003904A3 WO 2007003904 A3 WO2007003904 A3 WO 2007003904A3 GB 2006002424 W GB2006002424 W GB 2006002424W WO 2007003904 A3 WO2007003904 A3 WO 2007003904A3
Authority
WO
WIPO (PCT)
Prior art keywords
prevention
prophylactic
treatment
immunomodulatory compositions
sphingosine compound
Prior art date
Application number
PCT/GB2006/002424
Other languages
English (en)
Other versions
WO2007003904A2 (fr
Inventor
Marc Creus
Original Assignee
Kherion Technology Ltd
Marc Creus
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kherion Technology Ltd, Marc Creus filed Critical Kherion Technology Ltd
Priority to US11/994,050 priority Critical patent/US10092643B2/en
Publication of WO2007003904A2 publication Critical patent/WO2007003904A2/fr
Publication of WO2007003904A3 publication Critical patent/WO2007003904A3/fr
Priority to US16/152,910 priority patent/US20190175725A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Cette invention concerne l'utilisation d'un composé sphingosine, ou d'un dérivé d'un composé sphingosine, dans la fabrication d'un vaccin efficace dans le traitement et la prévention d'une maladie infectieuse et le traitement et/ou la prévention d'une maladie auto-immune. Cette invention concerne également l'utilisation d'un composé sphingosine, ou d'un dérivé d'un composé sphingosine, dans la fabrication d'un médicament immunomodulateur efficace dans la prévention d'une maladie infectieuse et le traitement et/ou la prévention d'une maladie auto-immune.
PCT/GB2006/002424 2005-06-30 2006-06-30 Compositions prophylactiques et immunomodulatrices et leurs utilisations WO2007003904A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US11/994,050 US10092643B2 (en) 2005-06-30 2006-06-30 Prophylactic and immunomodulatory compositions and uses
US16/152,910 US20190175725A1 (en) 2005-06-30 2018-10-05 Prophylactic and Immunomodulatory Compositions and Uses

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0513431.7 2005-06-30
GBGB0513431.7A GB0513431D0 (en) 2005-06-30 2005-06-30 Prophylactic compositions and uses

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US11/994,050 A-371-Of-International US10092643B2 (en) 2005-06-30 2006-06-30 Prophylactic and immunomodulatory compositions and uses
US16/152,910 Continuation US20190175725A1 (en) 2005-06-30 2018-10-05 Prophylactic and Immunomodulatory Compositions and Uses

Publications (2)

Publication Number Publication Date
WO2007003904A2 WO2007003904A2 (fr) 2007-01-11
WO2007003904A3 true WO2007003904A3 (fr) 2007-05-10

Family

ID=34856451

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2006/002424 WO2007003904A2 (fr) 2005-06-30 2006-06-30 Compositions prophylactiques et immunomodulatrices et leurs utilisations

Country Status (3)

Country Link
US (1) US10092643B2 (fr)
GB (1) GB0513431D0 (fr)
WO (1) WO2007003904A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20010688A1 (it) * 2001-11-21 2003-05-21 Univ Roma Composti immunoregolatori.
ITRM20120083A1 (it) * 2012-03-07 2013-09-08 Ist Superiore Sanita Uso di modulatori dei recettori della sfingosina 1 fosfato per migliorare le immunizzazioni vaccinali.
WO2014061016A1 (fr) * 2012-10-15 2014-04-24 Yeda Research And Development Co. Ltd. Utilisation de bases à chaînes longues sphingoïdes et de leurs analogues dans le traitement et la prévention d'infections bactériennes
EP3259990A1 (fr) * 2016-06-20 2017-12-27 Ceva Sante Animale Procédés pour lutter contre les ectoparasites chez les mammifères non humaines
IL260690A (en) 2018-07-19 2018-12-31 Yeda Res & Dev Sphingosine derivatives and their use against pulmonary bacterial infections
CA3139314A1 (fr) * 2019-07-17 2021-01-21 Noxopharm Limited Therapie immuno-oncologique a l'aide de composes d'isoflavone

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5256641A (en) * 1990-11-01 1993-10-26 State Of Oregon Covalent polar lipid-peptide conjugates for immunological targeting
US6147118A (en) * 1997-05-02 2000-11-14 Dsm N.V. Antimicrobial compositions for topical use
WO2003045365A2 (fr) * 2001-11-21 2003-06-05 Universita Degli Studi Di Roma 'tor Vergata' Composes immunoregulateurs
WO2004024673A1 (fr) * 2002-09-13 2004-03-25 Novartis Ag Derives d'amino-propanol
WO2004110496A1 (fr) * 2003-06-18 2004-12-23 Yissum Research Development Company Of The Hebrew University Of Jerusalem Conjugues sphingoide-polyalkylamine pour la preparation d'un vaccin

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0321287A3 (fr) 1987-12-18 1990-11-22 City of Hope Inhibition de lipogenèse
US5260288A (en) * 1992-04-03 1993-11-09 The Biomembrane Institute Method for inhibition of cell motility by sphingosine-1-phosphate and derivatives
KR100260110B1 (ko) * 1993-09-09 2000-07-01 라카일레 지. 필리페 담즙으로부터 추출된 면역조절제 조성물
US5430169A (en) * 1994-02-14 1995-07-04 The United States Of America Represented By The Department Of Health And Human Services Method for preparation of sphingoid bases
EP0754053A1 (fr) * 1995-02-03 1997-01-22 Korea Institute of Science and Technology Nouvelle composition hemostatique
WO1998052575A1 (fr) 1997-05-20 1998-11-26 The Trustees Of Columbia University In The City Of New York Utilisation d'inhibiteurs de la proteinase pour le traitement de l'emphyseme pulmonaire
JPH1180026A (ja) * 1997-09-02 1999-03-23 Yoshitomi Pharmaceut Ind Ltd 新規免疫抑制剤、その使用方法およびその同定方法
US6239297B1 (en) * 1997-09-11 2001-05-29 Takara Shuzo Co., Ltd. Sphingosine derivatives and medicinal composition
DE19810999A1 (de) 1998-03-13 1999-09-16 Dermapharm Gmbh Verwendung von Sphingosin, Sphingosin-1-Phosphat, Sphingosin-1-Phosphat-Derivaten und/oder deren Gemischen zur Behandlung von entzündlichen Hautkrankheiten
US6248329B1 (en) * 1998-06-01 2001-06-19 Ramaswamy Chandrashekar Parasitic helminth cuticlin nucleic acid molecules and uses thereof
WO2001051003A2 (fr) * 2000-01-10 2001-07-19 Yissum Research Development Company Of The Hebrew University Of Jerusalem Utilisation de conjugues de lipides dans le traitement de maladies
FR2823117A1 (fr) * 2000-11-14 2002-10-11 Pharmascience Lab Composition pharmaceutique ou cosmetique ainsi que l'utilisation d'au moins un compose actif pour inhiber la migration des cellules de langerhans
GB0030700D0 (en) 2000-12-15 2001-01-31 European Molecular Biology Lab Embl Membrane signalling networks
WO2002060405A1 (fr) 2001-01-29 2002-08-08 Cosmoferm B.V. Composition dermatologique veterinaire contenant une base sphingoide et/ou un derive de base sphingoide
CA2437358A1 (fr) 2001-01-30 2002-08-22 University Of Virginia Patent Foundation Agonistes et antagonistes de recepteurs de sphingosine-1-phosphate
NZ560662A (en) 2002-05-16 2009-09-25 Novartis Ag Use of EDG receptor binding agents in cancer
CN1708293A (zh) 2002-09-24 2005-12-14 诺瓦提斯公司 治疗脱髓鞘疾病的鞘氨醇－1－磷酸受体激动剂
NL1022443C2 (nl) * 2003-01-20 2004-07-22 Tno Sphingolipiden voor verbetering van de samenstelling van de darmflora.
JP4603531B2 (ja) 2003-04-30 2010-12-22 ノバルティス アーゲー スフィンゴシン−１−ホスフェートレセプターモジュレーターとしての、アミノプロパノール誘導体
JP2008504330A (ja) * 2004-06-29 2008-02-14 ヤド テクノロジーズ ゲゼルシャフト ミット ベシュレンクテル ハフツング スフィンゴ脂質由来医薬組成物
BRPI0514316A (pt) * 2004-08-13 2008-06-10 Praecis Pharm Inc métodos e composições para modulação de atividade de receptor de esfingosina-1-fosfato (s1p)

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5256641A (en) * 1990-11-01 1993-10-26 State Of Oregon Covalent polar lipid-peptide conjugates for immunological targeting
US6147118A (en) * 1997-05-02 2000-11-14 Dsm N.V. Antimicrobial compositions for topical use
WO2003045365A2 (fr) * 2001-11-21 2003-06-05 Universita Degli Studi Di Roma 'tor Vergata' Composes immunoregulateurs
WO2004024673A1 (fr) * 2002-09-13 2004-03-25 Novartis Ag Derives d'amino-propanol
WO2004110496A1 (fr) * 2003-06-18 2004-12-23 Yissum Research Development Company Of The Hebrew University Of Jerusalem Conjugues sphingoide-polyalkylamine pour la preparation d'un vaccin

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
EDWARD J. GOETZL ET AL.: "Regulation of immunity by lysosphingolipids and their G protein-coupled receptors", THE JOURNAL OF CLINICAL INVESTIGATION, vol. 114, no. 11, December 2004 (2004-12-01), pages 1531 - 1537, XP002404037 *
SANJAY K. GARG ET AL.: "Sphingosine 1-Phosphate induces antimicrobial activity both in vitro and in vivo", JOURNAL OF INFECTIOUS DISEASES, vol. 189, 1 June 2004 (2004-06-01), pages 2129 - 2138, XP008070182 *

Also Published As

Publication number Publication date
WO2007003904A2 (fr) 2007-01-11
US10092643B2 (en) 2018-10-09
US20100278903A1 (en) 2010-11-04
GB0513431D0 (en) 2005-08-10

Similar Documents

Publication Publication Date Title
WO2004094596A8 (fr) Nouvelles compositions immunogenes de prevention de traitement de meningococcie
IL245955B (en) Immunogenic preparations for the prevention and treatment of inflammatory bowel disease
EP1753777A4 (fr) METHODES ET COMPOSITIONS POUR LE TRAITEMENT ET LA PREVENTION D'UNE INFECTION PAR LE VIH AU MOYEN DE TRIM5a
EP2279662A3 (fr) 5,7,4'-trihydroxy-3',5'-diméthoxyflavone comme agent antibactérien
IL207575A0 (en) Vaccine for prevention and treatment of hiv infection
WO2006096439A3 (fr) Compositions pharmaceutiques destinees au traitement et/ou a la prevention de la schizophrenie et de maladies associees
AU2002360517A1 (en) Respiratory infection prevention and treatment with terpene-containing compositions
ZA200603065B (en) The use of anti biotics as vaccine adjuvants
IL178395A0 (en) Synergistic attenuation of vesicular stomatitis virus, vectors thereof and immunogenic compositions thereof
WO2005039630A3 (fr) Compositions immunogenes
WO2007079448A3 (fr) Vaccin glucidique à trois composants
EP1545599A4 (fr) Compositions immunogenes et utilisations diagnostiques et therapeutiques de celles-ci
WO2007003904A3 (fr) Compositions prophylactiques et immunomodulatrices et leurs utilisations
WO2009019294A3 (fr) Bromhydrate de bupropion et applications thérapeutiques
AU2006309007A8 (en) Use of vaccines for the treatment/ prevention of the transmission of influenza pathogens between species
AU2003270779A1 (en) Vaccine compositions and adjuvant
AU2003279551A1 (en) Use of resveratrol for the preparation of a medicament useful for the treatment of influenza virus infections
ZA200608358B (en) Synergistic attenuation of vesicular stomatitis virus, vectors thereof and immunogenic compositions thereof
WO2007057436A3 (fr) L’interferon dans la grippe
WO2007076091A3 (fr) Traitement d’infections virales utilisant un inhibiteur de facteur tissulaire
WO2006095173A3 (fr) Utilisation d'un compose
WO2005063757A3 (fr) Nouvelles formes cristallines de temozolomide
EP1635841A4 (fr) Action mirobicide, prophylactique et therapeutique de ctc-96 sur le papillomavirus
WO2003094962A3 (fr) Nouveau vaccin
WO2004093903A3 (fr) Procedes et compositions d'immunomodulation mettant en oeuvre des antigenes cd1

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06744301

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 11994050

Country of ref document: US